Company: INTS
Filing Date: 2025-12-04
Form Type: 8-K
Source: 0001567264-25-000109
Chunk: 0

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-12-04
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01. Other Events

On December 4, 2025, Intensity Therapeutics, Inc. (the “ Company”) filed a prospectus supplement to increase the capacity of its existing “at-the-market” offering program (the “ ATM”) to $30 million. While this filing increases the available capacity under the ATM, the Company is under no obligation to issue any shares (the “ Shares”) pursuant to the program. The expanded facility is intended to enhance the Company’s financial flexibility, providing an efficient mechanism to access capital if, and when, deemed appropriate. Any utilisation of the ATM will be at the discretion of the Company, taking into account prevailing market conditions and strategic priorities.

As previously disclosed, the ATM is conducted pursuant to the at the market offering agreement (the “ Offering Agreement”), dated July 3, 2024 (the “ Offering Agreement”) by and among the Company and H. C. Wainwright & Co. LLC (the “ Sales Agent). Accordingly, pursuant to the prospectus supplement, the amount of shares of the Company’s common stock, par value $0.0001 per share, that the Company may issue under the Offering Agreement has been increased to an aggregate of $30 million of Shares. There can be no assurance that the Sales Agent will be able to complete future placements pursuant to the Offering Agreement, even if instructed to do so. The number of Shares that the Company may ultimately sell under the Offering Agreement, if it chooses to do so, will fluctuate based on a number of factors, including the market price of its common stock during the sales period, the limits it may set in any instruction to sell Shares, and the demand for its common stock during an applicable sales period.

Attached hereto as Exhibit 5.1 to this Current Report is the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P. C., relating to the legality of the issuance and sale of the Shares.

Item 9.01. Financial Statements and Exhibits